Bel­licum halts tri­als af­ter se­ri­ous ad­verse event, looks for 's­trate­gic al­ter­na­tives'

Bel­licum Phar­ma­ceu­ti­cals is halt­ing the Phase I/II tri­als for the on­ly two can­di­dates in its pipeline af­ter re­port­ing a se­ri­ous ad­verse event — and is now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER